HROG12 T0 M1 Cells

HROG12 T0 M1 is a primary human glioblastoma multiforme (GBM) cell line established from freshly resected tumor tissue of an adult patient diagnosed with WHO grade IV glioblastoma. The designation “T0” indicates that the specimen was obtained at the initial surgical intervention, while “M1” refers to the corresponding in vitro model derived from this primary tumor. The cell line was generated within the HROG (Hansestadt Rostock Glioma) model platform, which focuses on establishing ultra-low passage glioma cultures that retain patient-specific molecular and biological characteristics.

HROG12 T0 M1 exhibits adherent growth under standard culture conditions and displays a fibroblast-like morphology typical of primary GBM cultures. Immunophenotypic characterization of HROG-derived cell lines demonstrates expression of neural and glial lineage markers such as glial fibrillary acidic protein (GFAP), nestin, and vimentin, supporting astrocytic tumor origin. Within the HROG collection, molecular profiling includes assessment of clinically relevant biomarkers such as MGMT promoter methylation, EGFR amplification status, and mutational analysis of genes including TP53, IDH1/2, KRAS, and BRAF, confirming preservation of tumor-associated genomic alterations in early passage cultures.

HROG12 T0 M1 has been used for in vitro evaluation of therapeutic responses to standard-of-care glioblastoma treatments, including alkylating agents, as well as investigational targeted therapies. Comparative analyses across HROG models indicate stable morphology, reproducible growth kinetics, and consistent drug sensitivity profiles in early passages. As a patient-derived, low-passage glioblastoma model, HROG12 T0 M1 provides a clinically relevant platform for studying tumor biology, molecular heterogeneity, and mechanisms of therapeutic resistance in high-grade glioma.